Slingshot members are tracking this event:

In February 2017, the data safety monitoring board recommended that FibroGen (FGEN) continue its Phase 3 roxadustat (FG-4592) programs

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
FGEN Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 28, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Roxadustat, Independent Data Safety Monitoring Board, Fg-4592